Blar i forfatter "Moen, Kåre"

Viser treff 1-3 av 3

    • Attendance to cervical cancer screening among Roma and non-Roma women living in North-Western region of Romania 

      Andreassen, Trude; Melnic, Adriana; Figueiredo, Rejane Augusta de Oliveira; Moen, Kåre; Şuteu, Ofelia; Nicula, Florian; Ursin, Giske; Weiderpass, Elisabete (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-04-27)
      <p><i>Objectives</i>: Romania has Europe’s highest incidence and mortality rates of cervical cancer. Participation in the national cervical cancer-screening programme is low, especially among minority Roma women.</p> <p><i>Methods</i>: We conducted a cross-sectional study, using a structured questionnaire aiming to quantify reasons for screening attendance among women in North-Western region of ...

    • Controversies about cervical cancer screening: A qualitative study of Roma women's (non)participation in cervical cancer screening in Romania 

      Andreassen, Trude; Weiderpass, Elisabete; Nicula, Florian; Suteu, Ofelia; Itu, Andreea; Bumbu, Minodora; Tincu, Aida; Ursin, Giske; Moen, Kåre (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-26)
      Romania has Europe's highest incidence and mortality of cervical cancer. While a free national cervical cancer-screening programme has been in operation since 2012, participation in the programme is low, particularly in minority populations. The aim of this study was to explore Roma women's (non)participation in the programme from women's own perspectives and those of healthcare providers and policy ...

    • Psychological effect of cervical cancer screening when changing primary screening method from cytology to high-risk human papilloma virus testing 

      Andreassen, Trude; Hansen, Bo Terning; Engesæter, Birgit Øvstebø; Hashim, Dana; Støer, Nathalie Charlotte; Trope, Ameli; Moen, Kåre; Ursin, Giske; Weiderpass, Elisabete (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-12-14)
      From 2015, Norway has implemented high‐risk human papilloma virus (hrHPV) testing in primary screening for cervical cancer. Women aged 34–69 years, living in four counties, have been pseudo‐randomly assigned (1:1 randomization) to either hrHPV testing every 5 years (followed by cytology if hrHPV is positive), or cytology testing every 3 years (followed by hrHPV testing if low‐grade cytology is ...